M. Aguiar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
M. Aguiar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
A. Bugalho de Almeida
Servio de Pneumologia 1, Hospital de Santa Maria, CHLN, EPE, Lisboa, Portugal
3 shared publicationsM. Felizardo
Interna do Complementar de Pneumologia/Resident, Pulmonology
3 shared publicationsA.C. Mendes
Servio de Pneumologia 1, Hospital de Santa Maria, CHLN, EPE, Lisboa, Portugal
2 shared publicationsF. Caeiro
Serviço de Pneumologia I, Hospital de Santa Maria, CHLN, EPE, Lisboa / Pulmonology Unit I, Hospital de Santa Maria, CHLN, EPE, Lisboa
2 shared publicationsR. Sotto-Mayor
Chefe de Serviço de Pneumologia/Head, Pulmonology Unit
2 shared publicationsA.A. Bugalho de Almeida
Serviço de Pneumologia I, Hospital de Santa Maria, CHLN, EPE, Lisboa / Pulmonology Unit I, Hospital de Santa Maria, CHLN, EPE, Lisboa
1 shared publication
Latest Publications
- Open Access
- 18 March 2011
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 17 (2) , 85-93
Infliximab for treating sarcoidosis patients, Portuguese experience
Despite aggressive treatment, sarcoidosis may be debilitating and progressive. The role of tumor necrosis factor (TNF) ap in the genesis of granulomas is ambiguous. It has proved to be critical in the formation and maintenance of granulomatous inflammation and its antagonist, Infl iximab, has therefore been used with success in the treatment of patients with sarcoidosis. There are, however, reports of onset of sarcoidosis in patients treated for other conditions and where there had been no outbursts before submission to this therapy. We used Infl iximab in the treatment of patients with sarcoidosis who either had not responded to corticosteroids and other conventional drugs or had developed unacceptable side effects to these drugs. The initial dose was 5 mg/kg body weight and subsequent doses were given at weeks 2, 4 and then every other 8 weeks for a total period of one year. We treated ten patients with biopsy proven sarcoidosis, five men and five women, with a mean age of 47.1 years ranging from 28 to 63 years of age. Three patients had severe neurological symptoms, two had hepatic cirrhosis, one had granulomatous inflammation of the lachrymal gland and had already undergone repeated surgery, one had extensive pulmonary involvement (stage III), one had disfiguring lupus pernio and two presented disabling cutaneous nodules. Eight patients had more than one organ with evidence of disease. All patients were submitted to at least seven infusions of Infliximab. In four patients the dosage of corticosteroids or other immunosuppressive drugs was suspended, in three the dosage was reduced and in one, corticosteroids were added to the Infl iximab therapy. In five of the patients there was an important improvement. One of the patients with neurological symptoms displayed a complete recovery, while another had significant improvement of vision deficit enabling her to read again. Two patients withdrew from therapy, one due to lack of improvement of neurological symptoms and the other due to the onset of organizing pneumonia spawned by Infl iximab. Two patients developed anti-histone antibodies during treatment.Infl iximab seems effective in treating patients who are either resistant or develop side effects to a standard regimen of corticosteroids and immunosuppressive agents. These patients, treated with Infl iximab, should be under tight surveillance in order to quickly identify possible secondary effects. Apesar de tratamento agressivo e atempado, a Sarcoidose pode ser, por vezes, uma doença progressiva e bastante debilitante. O papel do factor de necrose tumoral (TNF)-ap na génese dos granulomas é ambíguo. Por um lado a sua presença é necessária para a formação e manutenção da inflamação granulomatosa, sendo, portanto, o seu antagonista utilizado com sucesso no tratamento de doentes com sarcoidose; por outro lado e para outras situações, há referência do aparecimento dessa patologia em doentes submetidos a Infl iximab. O Infl iximab foi por nós utilizado no tratamento de doentes com sarcoidose que não apresentavam resposta à corticoterapia ou a outras terapêuticas convencionais ou que desenvolviam efeitos secundários inaceitáveis a essa terapêutica. A dose inicial foi de 5 mg/Kg de peso e as doses subsequentes foram administradas na 2.ª semana, na 6.ª semana e depois, durante o período de um ano de 8 em 8 semanas. Dez doentes com diagnóstico de sarcoidose por biopsia, iniciaram terapêutica com este fármaco. Destes cinco eram homens e cinco mulheres, com uma idade média de 47,1 anos, variando a idade entre 28 e 63 anos. Três doentes apresentavam sintomas graves do sistema nervoso central, dois, cirrose hepática, uma inflamação granulomatosa da glândula lacrimal já submetida a múltiplas cirurgias, uma com envolvimento pulmonar extenso (estádio III), uma, com lúpus pérnio desfigurante e dois, com nódulos cutâneos desfigurantes. Oito doentes apresentavam mais do que um local de doença. Todos os doentes completaram pelo menos sete ciclos de tratamento. Em quatro doentes a dose de corticóides ou de outra terapêutica imunosupressora foi suspensa, em três foi reduzida, e apenas em uma doente foi necessário juntar corticóides à terapêutica com Infl iximab. Cinco doentes apresentaram uma melhoria significativa. Um dos doentes com sintomas neurológicos apresentou resolução total, enquanto que a segunda melhorou substancialmente o seu deficit visual permitindo que voltasse a ler. Dois doentes suspenderam terapêutica, uma por falta de melhoria dos sintomas, neurológicos e outra por aparecimento de pneumonia organizativa durante o tratamento com Infl iximab. Três doentes desenvolveram anticorpos anti-histonas durante o tratamento. O Infl iximab parece ser eficaz no tratamento de doentes com sarcoidose refractária ou que desenvolvem efeitos secundários ao regime terapêutico habitual de corticóides ou outros agentes imunosupressivos. No entanto é necessário manter uma vigilância apertada destes doentes para identificar rapidamente efeitos secundários que possam surgir.
- 18 March 2011
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 17 (2) , 85-93
Open AccessInfliximab for treating sarcoidosis patients, Portuguese experience
Despite aggressive treatment, sarcoidosis may be debilitating and progressive. The role of tumor necrosis factor (TNF) ap in the genesis of granulomas is ambiguous. It has proved to be critical in the formation and maintenance of granulomatous inflammation and its antagonist, Infl iximab, has therefore been used with success in the treatment of patients with sarcoidosis. There are, however, reports of onset of sarcoidosis in patients treated for other conditions and where there had been no outbursts before submission to this therapy. We used Infl iximab in the treatment of patients with sarcoidosis who either had not responded to corticosteroids and other conventional drugs or had developed unacceptable side effects to these drugs. The initial dose was 5 mg/kg body weight and subsequent doses were given at weeks 2, 4 and then every other 8 weeks for a total period of one year. We treated ten patients with biopsy proven sarcoidosis, five men and five women, with a mean age of 47.1 years ranging from 28 to 63 years of age. Three patients had severe neurological symptoms, two had hepatic cirrhosis, one had granulomatous inflammation of the lachrymal gland and had already undergone repeated surgery, one had extensive pulmonary involvement (stage III), one had disfiguring lupus pernio and two presented disabling cutaneous nodules. Eight patients had more than one organ with evidence of disease. All patients were submitted to at least seven infusions of Infliximab. In four patients the dosage of corticosteroids or other immunosuppressive drugs was suspended, in three the dosage was reduced and in one, corticosteroids were added to the Infl iximab therapy. In five of the patients there was an important improvement. One of the patients with neurological symptoms displayed a complete recovery, while another had significant improvement of vision deficit enabling her to read again. Two patients withdrew from therapy, one due to lack of improvement of neurological symptoms and the other due to the onset of organizing pneumonia spawned by Infl iximab. Two patients developed anti-histone antibodies during treatment.Infl iximab seems effective in treating patients who are either resistant or develop side effects to a standard regimen of corticosteroids and immunosuppressive agents. These patients, treated with Infl iximab, should be under tight surveillance in order to quickly identify possible secondary effects. Apesar de tratamento agressivo e atempado, a Sarcoidose pode ser, por vezes, uma doença progressiva e bastante debilitante. O papel do factor de necrose tumoral (TNF)-ap na génese dos granulomas é ambíguo. Por um lado a sua presença é necessária para a formação e manutenção da inflamação granulomatosa, sendo, portanto, o seu antagonista utilizado com sucesso no tratamento de doentes com sarcoidose; por outro lado e para outras situações, há referência do aparecimento dessa patologia em doentes submetidos a Infl iximab. O Infl iximab foi por nós utilizado no tratamento de doentes com sarcoidose que não apresentavam resposta à corticoterapia ou a outras terapêuticas convencionais ou que desenvolviam efeitos secundários inaceitáveis a essa terapêutica. A dose inicial foi de 5 mg/Kg de peso e as doses subsequentes foram administradas na 2.ª semana, na 6.ª semana e depois, durante o período de um ano de 8 em 8 semanas. Dez doentes com diagnóstico de sarcoidose por biopsia, iniciaram terapêutica com este fármaco. Destes cinco eram homens e cinco mulheres, com uma idade média de 47,1 anos, variando a idade entre 28 e 63 anos. Três doentes apresentavam sintomas graves do sistema nervoso central, dois, cirrose hepática, uma inflamação granulomatosa da glândula lacrimal já submetida a múltiplas cirurgias, uma com envolvimento pulmonar extenso (estádio III), uma, com lúpus pérnio desfigurante e dois, com nódulos cutâneos desfigurantes. Oito doentes apresentavam mais do que um local de doença. Todos os doentes completaram pelo menos sete ciclos de tratamento. Em quatro doentes a dose de corticóides ou de outra terapêutica imunosupressora foi suspensa, em três foi reduzida, e apenas em uma doente foi necessário juntar corticóides à terapêutica com Infl iximab. Cinco doentes apresentaram uma melhoria significativa. Um dos doentes com sintomas neurológicos apresentou resolução total, enquanto que a segunda melhorou substancialmente o seu deficit visual permitindo que voltasse a ler. Dois doentes suspenderam terapêutica, uma por falta de melhoria dos sintomas, neurológicos e outra por aparecimento de pneumonia organizativa durante o tratamento com Infl iximab. Três doentes desenvolveram anticorpos anti-histonas durante o tratamento. O Infl iximab parece ser eficaz no tratamento de doentes com sarcoidose refractária ou que desenvolvem efeitos secundários ao regime terapêutico habitual de corticóides ou outros agentes imunosupressivos. No entanto é necessário manter uma vigilância apertada destes doentes para identificar rapidamente efeitos secundários que possam surgir.
- Open Access
- 31 May 2010
- Published by Taylor & Francis in Pulmonology
- Vol. 16 (3) , 369-389
Pneumonia organizativa – Experiência da consulta de um hospital central
To characterise outpatients of a Portuguese central hospital diagnosed with organising pneumonia (OP) and compare results with current literature. medical processes with diagnosis of OP were retrospectively studied as to demographics, aetiology, clinical and radiological features, average time until and date of diagnosis, laboratory and histological changes, treatment and relapse. Results - thirteen patients with a mean follow -up of 171.6 weeks (max 334 and min 28 weeks) were evaluated. Nine of these patients (70%) had cryptogenic OP (COP) while 30% had secondary OP (SOP), two with rheumatoid arthritis, one with dermatomyositis and another undergoing radiotherapy for breast cancer. Mean age was 55.6 (+ -15.3 years), 92% female, 77% were non -smokers. Average time until diagnosis was 77.2 weeks (min 3 and max 432 weeks). Symptoms at presentation were tiredness (92%), cough (85%), fever (65%), shortness of breath (54%), thoracic pain (23%) and weight loss (23%). At the time of diagnosis, the mean erythrocyte sedimentation rate was 70mm (max 170mm and min 16mm). C -reactive protein level was increased in eight patients. Significant leucocytosis was absent. Chest X -ray and chest CT scan showed bilateral distribution in 12 patients (92%). Consolidation with an air bronchogram was present in 12 patients and in four (31%), consolidation was migratory. Four patients (30%) underwent transbronchial pulmonary biopsy, all uncharacteristic and eight patients surgical pulmonary biopsy, four showed histological confirmation of SOP. Corticosteroids were started in 11 patients and average treatment was 61.6 weeks (16-288 weeks). 15% (2/13) had spontaneous resolution. Four patients (31%) relapsed, one of them five times. Two patients are dependent on a low dose of corticosteroids, one due to underlying disease and another due to multiple relapses. Therapy of relapse was corticosteroids alone in minimum effective dosage or associated to azathioprine or ciclosporin. such a high incidence in females (92%) may be explained by the limited sample of patients. In 70% of the patients diagnosis were established by clinical and radiology criteria. Mean time to diagnosis was very variable which suggests that in some cases the disease was not diagnosed and treated as another interstitial lung disease or as recurrent pneumonia. Most patients (53.8%) had a favourable clinical course after treatment with corticosteroids with a very low number of relapses (30.8%), much lower than described by other authors (60%). Only in experienced centres should the diagnosis of OP established by clinical and radiological criteria.
- 31 May 2010
- Published by Taylor & Francis in Pulmonology
- Vol. 16 (3) , 369-389
Open AccessPneumonia organizativa – Experiência da consulta de um hospital central
To characterise outpatients of a Portuguese central hospital diagnosed with organising pneumonia (OP) and compare results with current literature. medical processes with diagnosis of OP were retrospectively studied as to demographics, aetiology, clinical and radiological features, average time until and date of diagnosis, laboratory and histological changes, treatment and relapse. Results - thirteen patients with a mean follow -up of 171.6 weeks (max 334 and min 28 weeks) were evaluated. Nine of these patients (70%) had cryptogenic OP (COP) while 30% had secondary OP (SOP), two with rheumatoid arthritis, one with dermatomyositis and another undergoing radiotherapy for breast cancer. Mean age was 55.6 (+ -15.3 years), 92% female, 77% were non -smokers. Average time until diagnosis was 77.2 weeks (min 3 and max 432 weeks). Symptoms at presentation were tiredness (92%), cough (85%), fever (65%), shortness of breath (54%), thoracic pain (23%) and weight loss (23%). At the time of diagnosis, the mean erythrocyte sedimentation rate was 70mm (max 170mm and min 16mm). C -reactive protein level was increased in eight patients. Significant leucocytosis was absent. Chest X -ray and chest CT scan showed bilateral distribution in 12 patients (92%). Consolidation with an air bronchogram was present in 12 patients and in four (31%), consolidation was migratory. Four patients (30%) underwent transbronchial pulmonary biopsy, all uncharacteristic and eight patients surgical pulmonary biopsy, four showed histological confirmation of SOP. Corticosteroids were started in 11 patients and average treatment was 61.6 weeks (16-288 weeks). 15% (2/13) had spontaneous resolution. Four patients (31%) relapsed, one of them five times. Two patients are dependent on a low dose of corticosteroids, one due to underlying disease and another due to multiple relapses. Therapy of relapse was corticosteroids alone in minimum effective dosage or associated to azathioprine or ciclosporin. such a high incidence in females (92%) may be explained by the limited sample of patients. In 70% of the patients diagnosis were established by clinical and radiology criteria. Mean time to diagnosis was very variable which suggests that in some cases the disease was not diagnosed and treated as another interstitial lung disease or as recurrent pneumonia. Most patients (53.8%) had a favourable clinical course after treatment with corticosteroids with a very low number of relapses (30.8%), much lower than described by other authors (60%). Only in experienced centres should the diagnosis of OP established by clinical and radiological criteria.
- Open Access
- 30 May 2009
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 15 (3) , 419-431
Obstructive sleep apnoea syndrome as a cause of road traffic accidents
Several studies have demonstrated that obstructive sleep apnoea syndrome (OSAS) patients have a higher rate of road traffic accidents. Our study aimed to analyse any differences in OSAS patients between those who reported having had road traffic accidents and/or near misses and those who did not. Methods: We studied 163 patients with OSAS (apnoea- hypopnoea index (AHI) > 10/h) diagnosed using nocturnal polysomnography (NPSG), all drivers, 18.4% of whom drove for a living. Patients were asked at their first clinical interview to self-report road traffic accidents and/or near misses over the past 3 years which had been caused by abnormal daytime drowsiness. This allowed patients to be divided into two groups, those who had had road traffic accidents and/or near misses and those who had not. Both were compared as to age, body mass index (BMI), Epworth Sleepiness Scale (ESS), daytime PaO2 and PaCO2, Functional Outcomes of Sleep Questionnaire (FOSQ) test and NPSG data. This latter was total sleep time (TTS), sleep efficiency, sleep stages, arousal index (ARI), AHI, minimal and average SaO2, % of time with SaO2 < 90% (T90), desaturation index (ODI), total duration of apnoea-hypopnoea (TDAH) (T test). Results: Group I (no road traffic accidents) No = 89 patients; group II (road traffic accidents) No = 74 patients. Age (years) was 57.6 ± 11.8 vs. 54.7 ± 10.9 (ns); male gender, 75% vs. 78.4%; ESS, 12.3 ± 5.4 vs. 17.6 ± 4.3 (p < 0.001); BMI, (Kg/m2) 36.2 ± 8.1 vs. 35.6 ± 6.3 (ns); PaO2 (mmHg), 76.1 ± 11.4 vs. 78.5 ± 12.6 (ns); PaCO2 (mmHg), 42.6 ± 5.1 vs. 42.2 ± 4.7 (ns); FOSQ, 15.1 ± 3.1 vs. 12.9 ± 3.4 (p < 0.001). NPSG data revealed differences only in AHI: 45.0 ± 21.6 vs. 56.2 ± 29.7 (p = 0.01) and in TDAH (minutes), 98.5 ± 63.7 vs. 133.3 ± 83.2 (p = 0,005). Conclusions: In our experience patients who had road traffic accidents and/or near misses had a more severe OSAS, with higher AHI, excessive daytime sleepiness and lower quality of life. Vários estudos demonstram que os doentes com síndroma de apneia obstrutiva do sono (SAOS) têm um risco aumentado de acidentes de viação. O objectivo do presente trabalho consistiu em analisar, nestes doentes, se há diferenças nos que referem acidentes e//ou quase acidentes e aqueles que o não fazem. Material e métodos: Estudaram-se prospectivamente 163 doentes com SAOS (índice apneia/hipopneia (IAH) > 10/h) diagnosticados por polissonografia nocturna (PSG), todos condutores de veículos, 18,4% do quais profissionais. Na altura da entrevista clínica foi inquirido se tinham tido, nos três anos antes acidentes e/ou quase acidentes devido a hipersonia diurna (Grupo II = 74) ou não (Grupo I = 89). Estes dois grupos foram comparados quanto a: idade, índice de massa corporal (IMC), escala de sonolência de Epworth (ESE), PaO2 e PaCO2 diurnas, avaliação da qualidade de vida pelo inquérito Functional Outcomes of Sleep Questionnaire (FOSQ teste) e dados da polissonografia – tempo total de sono (TTS), eficiência do sono, estádios do sono, índice de microdespertares (IMD), índice de apneia/hipopneia (IAH), SaO2 mínima e média, % tempo SaO2 < 90% (T90), índice de dessaturação (IDS), tempo total em apneia/hipopneia (TTOT) (teste t de Student). Resultados: (Grupo I / Grupo II) idade (anos) – 57,6 ± 11,8 / 54,7 ± 10,9 (ns); sexo masculino – 75%/78,4%; ESE – 12,3 ± 5,4 / 17,6 ± 4,3 (p < 0,001); IMC (kg/m2) – 36,2 ± 8,1 / 35,6 ± 6,3 (ns); PaO2 (mmHg) – 76,1 ± 11,4 / 78,5 ± 12,6 (ns); PaCO2 (mmHg) – 42,6 ± 5,1 / 42,2 ± 4,7 (ns); FOSQ test – 15,1 ± 3,1/12,9 ± 3,4 (p < 0,001). Dos dados da PSG só se encontraram diferenças no IAH – 45,0 ± 21,6 / 56,2 ± 29.7 (p = 0,01) e no TTOT (minutos) – 98,5 ± 63,7 / 133,3 ± 83,2 (p = 0,005). Conclusões: Nesta experiência, os doentes com acidentes e/ou quase acidentes tinham uma SAOS mais grave, nomeadamente com maiores IAH e hipersonia diurna, e menor qualidade de vida.
- 30 May 2009
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 15 (3) , 419-431
Open AccessObstructive sleep apnoea syndrome as a cause of road traffic accidents
Several studies have demonstrated that obstructive sleep apnoea syndrome (OSAS) patients have a higher rate of road traffic accidents. Our study aimed to analyse any differences in OSAS patients between those who reported having had road traffic accidents and/or near misses and those who did not. Methods: We studied 163 patients with OSAS (apnoea- hypopnoea index (AHI) > 10/h) diagnosed using nocturnal polysomnography (NPSG), all drivers, 18.4% of whom drove for a living. Patients were asked at their first clinical interview to self-report road traffic accidents and/or near misses over the past 3 years which had been caused by abnormal daytime drowsiness. This allowed patients to be divided into two groups, those who had had road traffic accidents and/or near misses and those who had not. Both were compared as to age, body mass index (BMI), Epworth Sleepiness Scale (ESS), daytime PaO2 and PaCO2, Functional Outcomes of Sleep Questionnaire (FOSQ) test and NPSG data. This latter was total sleep time (TTS), sleep efficiency, sleep stages, arousal index (ARI), AHI, minimal and average SaO2, % of time with SaO2 < 90% (T90), desaturation index (ODI), total duration of apnoea-hypopnoea (TDAH) (T test). Results: Group I (no road traffic accidents) No = 89 patients; group II (road traffic accidents) No = 74 patients. Age (years) was 57.6 ± 11.8 vs. 54.7 ± 10.9 (ns); male gender, 75% vs. 78.4%; ESS, 12.3 ± 5.4 vs. 17.6 ± 4.3 (p < 0.001); BMI, (Kg/m2) 36.2 ± 8.1 vs. 35.6 ± 6.3 (ns); PaO2 (mmHg), 76.1 ± 11.4 vs. 78.5 ± 12.6 (ns); PaCO2 (mmHg), 42.6 ± 5.1 vs. 42.2 ± 4.7 (ns); FOSQ, 15.1 ± 3.1 vs. 12.9 ± 3.4 (p < 0.001). NPSG data revealed differences only in AHI: 45.0 ± 21.6 vs. 56.2 ± 29.7 (p = 0.01) and in TDAH (minutes), 98.5 ± 63.7 vs. 133.3 ± 83.2 (p = 0,005). Conclusions: In our experience patients who had road traffic accidents and/or near misses had a more severe OSAS, with higher AHI, excessive daytime sleepiness and lower quality of life. Vários estudos demonstram que os doentes com síndroma de apneia obstrutiva do sono (SAOS) têm um risco aumentado de acidentes de viação. O objectivo do presente trabalho consistiu em analisar, nestes doentes, se há diferenças nos que referem acidentes e//ou quase acidentes e aqueles que o não fazem. Material e métodos: Estudaram-se prospectivamente 163 doentes com SAOS (índice apneia/hipopneia (IAH) > 10/h) diagnosticados por polissonografia nocturna (PSG), todos condutores de veículos, 18,4% do quais profissionais. Na altura da entrevista clínica foi inquirido se tinham tido, nos três anos antes acidentes e/ou quase acidentes devido a hipersonia diurna (Grupo II = 74) ou não (Grupo I = 89). Estes dois grupos foram comparados quanto a: idade, índice de massa corporal (IMC), escala de sonolência de Epworth (ESE), PaO2 e PaCO2 diurnas, avaliação da qualidade de vida pelo inquérito Functional Outcomes of Sleep Questionnaire (FOSQ teste) e dados da polissonografia – tempo total de sono (TTS), eficiência do sono, estádios do sono, índice de microdespertares (IMD), índice de apneia/hipopneia (IAH), SaO2 mínima e média, % tempo SaO2 < 90% (T90), índice de dessaturação (IDS), tempo total em apneia/hipopneia (TTOT) (teste t de Student). Resultados: (Grupo I / Grupo II) idade (anos) – 57,6 ± 11,8 / 54,7 ± 10,9 (ns); sexo masculino – 75%/78,4%; ESE – 12,3 ± 5,4 / 17,6 ± 4,3 (p < 0,001); IMC (kg/m2) – 36,2 ± 8,1 / 35,6 ± 6,3 (ns); PaO2 (mmHg) – 76,1 ± 11,4 / 78,5 ± 12,6 (ns); PaCO2 (mmHg) – 42,6 ± 5,1 / 42,2 ± 4,7 (ns); FOSQ test – 15,1 ± 3,1/12,9 ± 3,4 (p < 0,001). Dos dados da PSG só se encontraram diferenças no IAH – 45,0 ± 21,6 / 56,2 ± 29.7 (p = 0,01) e no TTOT (minutos) – 98,5 ± 63,7 / 133,3 ± 83,2 (p = 0,005). Conclusões: Nesta experiência, os doentes com acidentes e/ou quase acidentes tinham uma SAOS mais grave, nomeadamente com maiores IAH e hipersonia diurna, e menor qualidade de vida.
- Open Access
- 18 March 2009
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia
- Vol. 15 (2) , 179-197
Four years’ follow up at a smoking cessation clinic
Smoking is an important cause of pulmonary pathology and this addiction can be regarded as a chronic, recurrent disease. The benefits of smoking cessation are unquestionable and all physicians should become more active and assertive in recommending it. To characterise the population seeking medical support for smoking cessation and understand why some successfully stop smoking and others do not. Retrospective analysis of medical records of outpatients in follow-up between January 2003 and June 2006. Age, gender, age at smoking initiation, smoking burden (number of pack-years), associated diseases, degree of dependence (Fagerström test for nicotine addiction), prior attempts at and motivation for smoking cessation, need for cognitive/behavioural support and success and abandonment rates were evaluated. Five hundred and twenty six patients were studied, 50% male with an average age of 45.5+/-11.4 years. Almost half (43.1 %; n=227) of the patients started smoking before the age of 15. Average smoking burden was 35.8+/-20 pack-years although 21.4% (n=113) smoked more than 50 pack-years. Respiratory disease was present in 52.1% (COPD, 39.9% and others, 12.2%) and cardiovascular disease in 14.6% of the patients. In 46% of patients (n=242) a relevant psychiatric disorder was identified; depression (21.4%), anxiety disorder (19.4%), other dependencies (2.1%) bipolar disorder (1.5%) and schizophrenia (0.6%). The evaluation of degree of addiction revealed maximum level in 69.7% of the patients (n=380). Many patients (72.2%; n=380) reported prior attempts to quit smoking. The strongest reasons for giving up smoking were concern over health (83.5%), financial issues (8.2%) and search for better quality of life (5.7%). Most patients (81.7%; n=430) had undergone nicotine replacement therapy; skin patches (53.3%), chewing gum (1.1%) or both (45.6%). Psychopharmacological treatment included administration of sedative-hypnotics (86.5%), bupropion hydrochloride (2.3%) and antidepressants (0.6%). Seventy six patients (14%) benefited from cognitive/ behavioural support. Two hundred and twenty three patients (42.4%) were successful in giving up smoking while 219 (41.6%) abandoned follow up, the majority after the first appointment. Most patients that abandoned follow up reported lack of motivation and the price of therapy. The population under study had a high rate of psychiatric disorders and a high level of dependence and lack of motivation that might justify the drop-out rate. Successful treatment was associated with close follow up, behavioural support and pharmacological therapy.
- 18 March 2009
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia
- Vol. 15 (2) , 179-197
Open AccessFour years’ follow up at a smoking cessation clinic
Smoking is an important cause of pulmonary pathology and this addiction can be regarded as a chronic, recurrent disease. The benefits of smoking cessation are unquestionable and all physicians should become more active and assertive in recommending it. To characterise the population seeking medical support for smoking cessation and understand why some successfully stop smoking and others do not. Retrospective analysis of medical records of outpatients in follow-up between January 2003 and June 2006. Age, gender, age at smoking initiation, smoking burden (number of pack-years), associated diseases, degree of dependence (Fagerström test for nicotine addiction), prior attempts at and motivation for smoking cessation, need for cognitive/behavioural support and success and abandonment rates were evaluated. Five hundred and twenty six patients were studied, 50% male with an average age of 45.5+/-11.4 years. Almost half (43.1 %; n=227) of the patients started smoking before the age of 15. Average smoking burden was 35.8+/-20 pack-years although 21.4% (n=113) smoked more than 50 pack-years. Respiratory disease was present in 52.1% (COPD, 39.9% and others, 12.2%) and cardiovascular disease in 14.6% of the patients. In 46% of patients (n=242) a relevant psychiatric disorder was identified; depression (21.4%), anxiety disorder (19.4%), other dependencies (2.1%) bipolar disorder (1.5%) and schizophrenia (0.6%). The evaluation of degree of addiction revealed maximum level in 69.7% of the patients (n=380). Many patients (72.2%; n=380) reported prior attempts to quit smoking. The strongest reasons for giving up smoking were concern over health (83.5%), financial issues (8.2%) and search for better quality of life (5.7%). Most patients (81.7%; n=430) had undergone nicotine replacement therapy; skin patches (53.3%), chewing gum (1.1%) or both (45.6%). Psychopharmacological treatment included administration of sedative-hypnotics (86.5%), bupropion hydrochloride (2.3%) and antidepressants (0.6%). Seventy six patients (14%) benefited from cognitive/ behavioural support. Two hundred and twenty three patients (42.4%) were successful in giving up smoking while 219 (41.6%) abandoned follow up, the majority after the first appointment. Most patients that abandoned follow up reported lack of motivation and the price of therapy. The population under study had a high rate of psychiatric disorders and a high level of dependence and lack of motivation that might justify the drop-out rate. Successful treatment was associated with close follow up, behavioural support and pharmacological therapy.